The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity ...
The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving ...
In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...
Despite some angst over pricing pressure for GLP-1 drugs, Lilly’s bullish projections surpassed consensus estimates, while ...
Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results